| Revenue growth | FY26 growth 3% YoY; Q4 grew 2% YoY. |
|---|---|
| Margins | FY26 EBITDA margin 25%; FY27 guided to mid-20s. |
| Order book | Extension of BMS partnership to 2035 provides long-term visibility. |
| Demand visibility | Strong interest in Unit 3 biologics and ADC discovery lab. |
| Management confidence | Confident in long-term momentum despite near-term Librela and leadership transitions. |
Growth
FY26 revenue up 3% YoY; Q4 revenue INR 1,037 Cr (up 2% YoY, 13% QoQ). FY26 PAT before exceptions down 20%.
Outlook
FY27 revenue guidance flat YoY; growth weighted to H2. Targeting strategic reset for stronger growth from FY28 onwards.
Risks
Continued Librela destocking impact through H1 FY27; geopolitical uncertainties; high staff and utility costs from new facilities.
Earnings Call filed with NSE, NSE: SYNGENE. Summary written with AI assistance from the document.
Syngene International Ltd: key numbers
- Share price
- ₹360.15
- Market cap
- ₹14,538 Cr
- Revenue (annual)
- ₹3,739 Cr
- Net profit (annual)
- ₹316.7 Cr
- P/E (TTM)
- 65.8×Sector 47.4×
- Promoter holding
- 52.59%-0.09% QoQ
- FII holding
- 11.82%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Syngene International Ltd
All →Syngene International Management Change
Syngene International Limited announced the resignation of Mr. Pramuch Goel, Head of Corporate Affairs & Communications and Senior Management Personnel, effective September 21, 2026.
Syngene International Other Announcement
Syngene International Limited has issued a communication to shareholders regarding the remittance of the final dividend for the financial year 2025-26.
Syngene International Employee Stock Options
Syngene International has granted 14,26,061 Performance Share Units (PSUs) to eligible employees under the company's 2023 Long Term Incentive Performance Share Plan.
Syngene International Acquisition Worth ₹2.52 Cr
Syngene International Limited is investing ₹2.52 Crore to acquire a 12.44% equity stake in Ampin C&I Power Twelve Private Limited for renewable energy power consumption.
- Value
- ₹2.52 Cr
Syngene International Investor Presentation: Key Takeaways
Syngene reports Q1 FY27 revenue of Rs 736 Cr (-16% YoY). Performance was impacted by low offtake from a major client and forex losses.
Syngene International Annual General Meeting
Syngene International Limited held its 33rd Annual General Meeting on July 29, 2026. The meeting transacted business including the adoption of financial statements and dividend declaration.